Kolltan Approaching First IND Submission For RTK-Targeted Oncology Drug Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Having raised about $75 million in venture funding since its 2007 inception, Kolltan Pharmaceuticals is getting closer to the clinic with novel oncology candidates targeting receptor tyrosine kinases.
You may also be interested in...
Kolltan Raises $60 Million Series D, But Keeps Mum About Cancer Program
Never a company known to offer much detail about its plans, Kolltan has raised a $60 million Series D led by an undisclosed global institutional asset manager. Its lead program is in Phase I with the biotech planning a Phase II program combining KTN3379 with other cancer therapies.
With Kolltan, Kinase Veteran Schlessinger Turns To Antibodies
Joseph Schlessinger’s insights into receptor tyrosine kinases (RTKs) led to small-molecule treatments and huge success at Sugen and Plexxikon. Schlessinger’s latest venture, Kolltan Pharmaceuticals, had little trouble raising $75 million, but powering up a pipeline of antibodies to target novel RTKs has proven more challenging.
Deals Of The Week: Tellingly, Teva And Lonza Part Ways
Teva and Lonza agree to dissolve their four-year-old biosimilars joint venture, created at a time when the biosimilars opportunity seemed huge, if vague. In an otherwise slow deal-making week, next-generation antibody platform company Adimab forged two transforming deals with GSK and Biogen, while Kolltan and the Children’s Hospital of Philadelphia plunged into neuroblastoma.